Integrative Diagnosis for SCD and Other RADs

Recruiting Observational Study
Sickle Cell Disease Thalassaemia Congenital Dyserythropoietic Anemia (CDA) Enzyme Disorder; Anemia Spherocytosis, Hereditary Stomatocytosis Hemoglobin Disorder Anemia Due to Membrane Defect Rare Anemia Disorders
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
200 (estimated)
Sponsor
Hospital Universitari Vall d'Hebron Research Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia: * Sickle cell disease * Thalassemic syndromes * Congenital dyserythropoietic anemia * Enzymopathy * Unstable Hemoblogin / Altered oxygen affinity * Hereditary stomatocytosis * Heredi…
Contacts

Mar Mañú Pereira PhD

+34 93 489 4063

mar.manu@vhir.org

CONTACT